DOR, TTP, and time to response
| . | Cohort 1, 20 mg/m2 (n = 59) . | Cohort 2, 20/27 mg/m2 (n = 67) . | Total (N = 126) . |
|---|---|---|---|
| DOR, mo* | |||
| N | 25 | 35 | 60 |
| Median, mo (95% CI) | 13.1 (7.2-NR) | NR (NR-NR) | NR (13.1-NR) |
| Duration of CBR, mo | |||
| N | 35 | 43 | 78 |
| Median, (95% CI) | 11.5 (6.2-NR) | NR (NR-NR) | NR (11.5-NR) |
| TTP, mo | |||
| N | 59 | 67 | 126 |
| Median (95% CI) | 8.3 (6.0-12.3) | NR (11.3-NR) | 12.0 (8.2-NR) |
| Time to response, mo | |||
| N | 25 | 35 | 60 |
| Median, (min, max) | 1.0 (0.5, 3.7) | 1.9 (0.5, 3.7) | 1.7 (0.5-3.7) |
| Time to CBR, mo | |||
| N | 35 | 43 | 78 |
| Median, (min, max) | 0.5 (0.5, 6.5) | 0.5 (0.5, 5.9) | 0.5 (0.5-6.5) |
| . | Cohort 1, 20 mg/m2 (n = 59) . | Cohort 2, 20/27 mg/m2 (n = 67) . | Total (N = 126) . |
|---|---|---|---|
| DOR, mo* | |||
| N | 25 | 35 | 60 |
| Median, mo (95% CI) | 13.1 (7.2-NR) | NR (NR-NR) | NR (13.1-NR) |
| Duration of CBR, mo | |||
| N | 35 | 43 | 78 |
| Median, (95% CI) | 11.5 (6.2-NR) | NR (NR-NR) | NR (11.5-NR) |
| TTP, mo | |||
| N | 59 | 67 | 126 |
| Median (95% CI) | 8.3 (6.0-12.3) | NR (11.3-NR) | 12.0 (8.2-NR) |
| Time to response, mo | |||
| N | 25 | 35 | 60 |
| Median, (min, max) | 1.0 (0.5, 3.7) | 1.9 (0.5, 3.7) | 1.7 (0.5-3.7) |
| Time to CBR, mo | |||
| N | 35 | 43 | 78 |
| Median, (min, max) | 0.5 (0.5, 6.5) | 0.5 (0.5, 5.9) | 0.5 (0.5-6.5) |
The table is based on a response-evaluable population.
CBR indicates clinical benefit response; DOR, duration of response; NR, not reached; and TTP, time to progression.
Calculated for ORR.